Compare Stocks: HIMS, META, SNAP, NVO, and LLY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HIMS Hims & Hers Health	$20.16 -3.1%	$27.95	$13.74 ▼ $40.99	$4.70B	2.53	22.33 million shs	5.09 million shs
LLY Eli Lilly and Company	$1,451.93 +1.0%	$1,231.13	$850.51 ▼ $1,460.00	$1.37T	0.4	2.95 million shs	991,863 shs
META Meta Platforms	$624.73 -0.6%	$678.62	$520.26 ▼ $779.82	$1.60T	1.28	18.08 million shs	4.46 million shs
NVO Novo Nordisk A/S	$40.59 -1.2%	$40.32	$35.12 ▼ $64.16	$181.21B	0.7	16.32 million shs	10.35 million shs
SNAP Snap	$5.23 -2.2%	$5.73	$3.81 ▼ $9.07	$8.84B	1.23	45.33 million shs	11.31 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HIMS Hims & Hers Health	+9.60%	-21.65%	-32.16%	-27.56%	-47.44%
LLY Eli Lilly and Company	+0.34%	+1.36%	+21.46%	+18.69%	+45.57%
META Meta Platforms	-1.97%	-0.20%	-15.37%	+5.68%	+0.27%
NVO Novo Nordisk A/S	+1.11%	-2.55%	+6.55%	-12.02%	-16.42%
SNAP Snap	+6.87%	-9.75%	-18.32%	+0.81%	-38.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HIMS Hims & Hers Health	$20.16 -3.1%	$27.95	$13.74 ▼ $40.99	$4.70B	2.53	22.33 million shs	5.09 million shs
LLY Eli Lilly and Company	$1,451.93 +1.0%	$1,231.13	$850.51 ▼ $1,460.00	$1.37T	0.4	2.95 million shs	991,863 shs
META Meta Platforms	$624.73 -0.6%	$678.62	$520.26 ▼ $779.82	$1.60T	1.28	18.08 million shs	4.46 million shs
NVO Novo Nordisk A/S	$40.59 -1.2%	$40.32	$35.12 ▼ $64.16	$181.21B	0.7	16.32 million shs	10.35 million shs
SNAP Snap	$5.23 -2.2%	$5.73	$3.81 ▼ $9.07	$8.84B	1.23	45.33 million shs	11.31 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HIMS Hims & Hers Health	+9.60%	-21.65%	-32.16%	-27.56%	-47.44%
LLY Eli Lilly and Company	+0.34%	+1.36%	+21.46%	+18.69%	+45.57%
META Meta Platforms	-1.97%	-0.20%	-15.37%	+5.68%	+0.27%
NVO Novo Nordisk A/S	+1.11%	-2.55%	+6.55%	-12.02%	-16.42%
SNAP Snap	+6.87%	-9.75%	-18.32%	+0.81%	-38.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HIMS Hims & Hers Health	2.13	Hold	$31.53	51.19% Upside
LLY Eli Lilly and Company	2.86	Moderate Buy	$1,416.64	-1.45% Downside
META Meta Platforms	2.93	Moderate Buy	$833.12	32.50% Upside
NVO Novo Nordisk A/S	2.00	Hold	$59.44	44.52% Upside
SNAP Snap	2.30	Hold	$7.31	36.91% Upside

Current Analyst Ratings Breakdown

Latest HIMS, META, SNAP, NVO, and LLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/10/2026	HIMS Hims & Hers Health	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Hold	$31.00 ➝ $24.00
11/10/2026	HIMS Hims & Hers Health	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Equal Weight	$28.00 ➝ $25.00
11/10/2026	HIMS Hims & Hers Health	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$42.00 ➝ $32.00
11/9/2026	LLY Eli Lilly and Company	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$1,610.00 ➝ $1,700.00
11/6/2026	SNAP Snap	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$6.75 ➝ $6.00
11/5/2026	SNAP Snap	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$7.00
11/5/2026	SNAP Snap	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
11/5/2026	SNAP Snap	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$7.00 ➝ $6.00
11/5/2026	SNAP Snap	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Underweight	$6.00 ➝ $5.00
11/5/2026	SNAP Snap	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$16.00 ➝ $8.00
11/5/2026	SNAP Snap	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$6.00 ➝ $5.00

(Data available from 11/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HIMS Hims & Hers Health	$2.87B	1.70	$0.91 per share	22.86	$1.52 per share	13.72
LLY Eli Lilly and Company	$65.18B	20.75	$25.23 per share	56.98	$42.81 per share	33.58
META Meta Platforms	$200.97B	8.00	$36.81 per share	17.08	$106.56 per share	5.90
NVO Novo Nordisk A/S	$333.65B	0.55	$4.74 per share	8.68	$7.51 per share	5.48
SNAP Snap	$5.93B	1.52	N/A	N/A	$1.32 per share	4.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HIMS Hims & Hers Health	$128.37M	-$0.83	N/A	47.40	N/A	-6.65%	-9.62%	-1.38%	N/A
LLY Eli Lilly and Company	$20.64B	$30.81	46.66	28.71	1.72	31.90%	86.76%	22.03%	N/A
META Meta Platforms	$60.46B	$29.33	21.44	18.54	1.11	31.15%	30.73%	18.08%	1/27/2027 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$3.97	10.36	11.92	1.40	33.99%	53.52%	19.49%	N/A
SNAP Snap	-$460.49M	-$0.09	N/A	66.73	N/A	-2.30%	-7.10%	-2.00%	N/A

Latest HIMS, META, SNAP, NVO, and LLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	HIMS Hims & Hers Health	$0.0563	$0.0280	-$0.0283	-$0.14	$893.13 million	$890.37 million
11/4/2026	Q3 2026	SNAP Snap	$0.0048	$0.03	+$0.0252	$0.03	$1.73 billion	$1.72 billion
10/29/2026	Q3 2026	LLY Eli Lilly and Company	$5.71	$7.48	+$1.77	$7.22	$22.58 billion	$24.40 billion
10/22/2026	Q3 2026	META Meta Platforms	$6.54	$7.40	+$0.86	$3.83	$63.34 billion	$64.60 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.92	0.48%	+15.18%	22.46%	11 Years
META Meta Platforms	$2.10	0.33%	N/A	7.16%	1 Years
NVO Novo Nordisk A/S	$0.81	1.97%	+21.74%	20.40%	N/A
SNAP Snap	N/A	N/A	N/A	N/A	N/A

Latest HIMS, META, SNAP, NVO, and LLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/26/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.54%	11/13/2026	11/13/2026	12/10/2026
9/10/2026	META Meta Platforms	quarterly	$0.5250	0.28%	9/21/2026	9/21/2026	9/28/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HIMS Hims & Hers Health	3.85	0.92	0.87
LLY Eli Lilly and Company	1.17	1.39	1.00
META Meta Platforms	0.30	1.90	1.90
NVO Novo Nordisk A/S	0.54	0.84	0.64
SNAP Snap	1.52	3.36	3.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HIMS Hims & Hers Health	63.52%
LLY Eli Lilly and Company	82.53%
META Meta Platforms	79.91%
NVO Novo Nordisk A/S	11.54%
SNAP Snap	47.52%

Insider Ownership

Company	Insider Ownership
HIMS Hims & Hers Health	11.76%
LLY Eli Lilly and Company	0.14%
META Meta Platforms	13.42%
NVO Novo Nordisk A/S	0.07%
SNAP Snap	22.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HIMS Hims & Hers Health	2,442	233.31 million	205.88 million	Optionable
LLY Eli Lilly and Company	50,000	940.74 million	939.43 million	Optionable
META Meta Platforms	78,865	2.56 billion	2.21 billion	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
SNAP Snap	5,261	1.69 billion	1.31 billion	Optionable

HIMS, META, SNAP, NVO, and LLY Headlines

Recent News About These Companies

Magnite vs. Snap: Which Ad Tech Stock Is a Better Buy Going Into 2027?

November 11 at 8:41 PM | fool.com

What Makes Snap (SNAP) a New Buy Stock

November 11 at 1:01 PM | zacks.com

Snap (NYSE:SNAP) CTO Sells 2,000,000 Shares of Company Stock

November 11 at 5:07 AM | insidertrades.com

Snap (NYSE:SNAP) CTO Sells 2,000,000 Shares of Company Stock

November 10 at 11:07 PM | marketbeat.com

Snap (NYSE:SNAP) CTO Robert Murphy Sells 2,000,000 Shares of Stock

November 10 at 11:07 PM | marketbeat.com

Investing in Snap (SNAP)? Don't Miss Assessing Its International Revenue Trends

November 9 at 10:16 AM | zacks.com

Financial Contrast: Snap (NYSE:SNAP) vs. Bumble (NASDAQ:BMBL)

November 9 at 4:17 AM | americanbankingnews.com

Snap (NYSE:SNAP) Stock Gets Price Target Reduction from Citigroup

November 9 at 2:48 AM | americanbankingnews.com

Snap Q3 Earnings Call Highlights

November 8, 2026 | marketbeat.com

Pinterest vs. Snap: Which Media Stock Is a Better Buy Going into 2027?

November 8, 2026 | fool.com

Snap (SNAP) Faces New Lawsuits Over Alleged Snapchat Grooming Of Minors

November 8, 2026 | finance.yahoo.com

Snap (NYSE:SNAP) Stock Gets Price Target Cut from JPMorgan Chase & Co.

November 8, 2026 | americanbankingnews.com

Snap (NYSE:SNAP) Stock Gets Price Target Trim from UBS Group

November 8, 2026 | americanbankingnews.com

CenterBook Partners LP Purchases 762,979 Shares of Snap Inc. $SNAP

November 7, 2026 | marketbeat.com

Snap Inc. (SNAP): An Activist Target With High Cash

November 7, 2026 | finance.yahoo.com

Snap Inc. (SNAP): An Activist Target With High Cash

November 7, 2026 | insidermonkey.com

Tech companies face mounting child safety lawsuits while pushing AI into schools

November 7, 2026 | cnbc.com

Reviewing Snap (SNAP) and The Competition

November 7, 2026 | americanbankingnews.com

Snap Inc. (NYSE:SNAP) Stock Rated "Hold" by Wall Street Analysts

November 7, 2026 | americanbankingnews.com

Snap Inc. (NYSE:SNAP) Stock Has Consensus Target Price of $7.31 According to Brokerages

November 7, 2026 | marketbeat.com

Snap (NYSE:SNAP) Stock Rating Raised to "Buy" at Wall Street Zen

November 7, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HIMS, META, SNAP, NVO, and LLY Company Descriptions

Hims & Hers Health NYSE:HIMS

$20.16 -0.65 (-3.12%)

As of 12:20 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company NYSE:LLY

$1,451.93 +14.64 (+1.02%)

As of 12:20 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Meta Platforms NASDAQ:META

$624.73 -4.04 (-0.64%)

As of 12:20 PM Eastern

Meta Platforms, Inc. engages in the development of products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and wearables worldwide. It operates in two segments, Family of Apps and Reality Labs. The Family of Apps segment offers Facebook, which enables people to share, discuss, discover, and connect with interests; Instagram, a community for sharing photos, videos, and private messages, as well as feed, stories, reels, video, live, and shops; Messenger, a messaging application for people to connect with friends, family, communities, and businesses across platforms and devices through text, audio, and video calls; and WhatsApp, a messaging application that is used by people and businesses to communicate and transact privately. The Reality Labs segment provides augmented and virtual reality related products comprising consumer hardware, software, and content that help people feel connected, anytime, and anywhere. The company was formerly known as Facebook, Inc. and changed its name to Meta Platforms, Inc. in October 2021. The company was incorporated in 2004 and is headquartered in Menlo Park, California

Novo Nordisk A/S NYSE:NVO

$40.58 -0.51 (-1.23%)

As of 12:20 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Snap NYSE:SNAP

$5.22 -0.12 (-2.15%)

As of 12:20 PM Eastern

Snap Inc. operates as a technology company in North America, Europe, and internationally. The company offers Snapchat, a visual messaging application with various tabs, such as camera, visual messaging, snap map, stories, and spotlight that enable people to communicate visually through short videos and images. It also provides Spectacles, an eyewear product that connects with Snapchat and captures photos and video from a human perspective; and advertising products, including AR ads and Snap ads comprises a single image or video ads, collection ads, dynamic ads, story ads, and commercials. The company was formerly known as Snapchat, Inc. and changed its name to Snap Inc. in September 2016. Snap Inc. was founded in 2010 and is headquartered in Santa Monica, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HIMS, META, SNAP, NVO, and LLY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HIMS, META, SNAP, NVO, and LLY Earnings

Compare Dividends

Latest HIMS, META, SNAP, NVO, and LLY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HIMS, META, SNAP, NVO, and LLY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HIMS, META, SNAP, NVO, and LLY Company Descriptions

Hims & Hers Health NYSE:HIMS

Eli Lilly and Company NYSE:LLY

Meta Platforms NASDAQ:META

Novo Nordisk A/S NYSE:NVO

Snap NYSE:SNAP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools